Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma
Open Access
- 1 December 2023
- journal article
- research article
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 11 (12) , e007586
Abstract
Background: Pancreatic ductal adenocarcinoma (PDAC) is a challenging target for immunotherapy because it has an immunosuppressive tumor microenvironment. Neoadjuvant chemoradiotherapy can increase tumor-infiltrating lymphocyte (TIL) density, which may predict overall survival (OS). We hypothesized that adding programmed cell death protein 1 (PD-1) blockade to chemoradiotherapy would be well tolerated and increase TILs among patients with localized PDAC. Methods: Patients were randomized 2:1 to Arm A (receiving pembrolizumab plus chemoradiotherapy (capecitabine and external beam radiation)) or Arm B (receiving chemoradiotherapy alone) before anticipated pancreatectomy. Primary endpoints were (1) incidence and severity of adverse events during neoadjuvant therapy and (2) density of TILs in resected tumor specimens. TIL density was assessed using multiplexed immunofluorescence histologic examination. Results: Thirty-seven patients were randomized to Arms A (n=24) and B (n=13). Grade ≥3 adverse events related to neoadjuvant treatment were experienced by 9 (38%) and 4 (31%) patients in Arms A and B, respectively, with one patient experiencing dose-limiting toxicity in Arm A. Seventeen (71%) and 7 (54%) patients in Arms A and B, respectively, underwent pancreatectomy. Median CD8+ T-cell densities in Arms A and B were 67.4 (IQR: 39.2–141.8) and 37.9 (IQR: 22.9–173.4) cells/mm2, respectively. Arms showed no noticeable differences in density of CD8+Ki67+, CD4+, or CD4+FOXP3+ regulatory T cells; M1-like and M2-like macrophages; or granulocytes. Median OS durations were 27.8 (95% CI: 17.1 to NR) and 24.3 (95% CI: 12.6 to NR) months for Arms A and B, respectively. Conclusions: Adding pembrolizumab to neoadjuvant chemoradiotherapy was safe. However, no convincing effect on CD8+ TILs was observed.Keywords
Funding Information
- Francois Wallace Monahan Fund in loving memory of Michael Insel
- NIH grants (P50 CA127003, U01 CA210171, U01 CA274276-01)
- Wexler Family Fund
- Dana-Farber Cancer Institute Hale Family Center for Pancreatic Cancer Research
- Pancreatic Cancer Action Network
- Lustgarten Foundation dedicated laboratory program
- Noble Effort Fund
- Merck
- National Institute of General Medical Sciences (T32GM007753, T32GM144273)
- Stand Up To Cancer
- DFCI Hale Family Center for Pancreatic Cancer Research
This publication has 41 references indexed in Scilit:
- Irradiation and anti–PD-L1 treatment synergistically promote antitumor immunity in miceJournal of Clinical Investigation, 2014
- Cancer Immunotherapy2013
- Immunological Impact of Neoadjuvant Chemoradiotherapy in Patients with Borderline Resectable Pancreatic Ductal AdenocarcinomaAnnals of Surgical Oncology, 2013
- Influence of Patient, Physician, and Hospital Factors on 30-Day Readmission Following Pancreatoduodenectomy in the United StatesJAMA Surgery, 2013
- Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and PromotionScience, 2011
- Preoperative Capecitabine and Concurrent Radiation for Borderline Resectable Pancreatic CancerAnnals of Surgical Oncology, 2011
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Chemopreventive agents induce programmed death-1-ligand 1 (PD-L1) surface expression in breast cancer cells and promote PD-L1-mediated T cell apoptosisMolecular Immunology, 2008
- Dynamics of the Immune Reaction to Pancreatic Cancer from Inception to InvasionCancer Research, 2007
- Stromal fibroblasts in cancer initiation and progressionNature, 2004